Literature DB >> 28223425

Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145.

Guosong Jiang1,2, Chao Huang1,2, Jingxia Li1, Haishan Huang3, Honglei Jin3, Junlan Zhu1, Xue-Ru Wu4, Chuanshu Huang5.   

Abstract

Although miR-145 is the most frequently downregulated miRNA in bladder cancer, its exact stage association and downstream effector have not been defined. Here, we found that miR-145 was upregulated in human patients with bladder cancer with lymph node metastasis and in metastatic T24T cell line. Forced expression of miR-145 promoted anchorage-independent growth of T24T cells accompanied by the downregulation of forkhead box class O1 (FOXO1). In contrast, in non-metastatic T24 cells, miR-145 overexpression inhibited cell growth with upregulation of FOXO1, and the knockdown of FOXO1 abolished the miR-145-mediated inhibition of cell growth. Mechanistic studies revealed that miR-145 directly bound to and attenuated 3'-untranslated region (UTR) activity of foxo1 mRNA in both T24 and T24T cells. Interestingly, miR-145 suppressed STAT3 phosphorylation at Tyr705 and increased foxo1 promoter transcriptional activity in T24 cells, but not in T24T cells, suggesting a role of STAT3 in the divergent responses to miR-145. Supporting this was our finding that STAT3 knockdown mimicked miR-145-mediated upregulation of FOXO1 in T24T cells and inhibition of anchorage-independent growth. Consistently, ectopic expression of miR-145 promoted tumor formation of xenograft T24T cells, whereas such promoting effect became inhibitory due to specific knockdown of STAT3. Together, our findings demonstrate the stage-specific association and function of miR-145 in bladder cancers and provide novel insights into the therapeutic targeting of miR-145. Mol Cancer Ther; 16(5); 924-35. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28223425      PMCID: PMC5418086          DOI: 10.1158/1535-7163.MCT-16-0631

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  53 in total

1.  Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer.

Authors:  Philip Levy Ho; Erica Julianne Lay; Weiguo Jian; Diana Parra; Keith Syson Chan
Journal:  Cancer Res       Date:  2012-04-24       Impact factor: 12.701

Review 2.  RhoGDI signaling provides targets for cancer therapy.

Authors:  Michael A Harding; Dan Theodorescu
Journal:  Eur J Cancer       Date:  2010-03-27       Impact factor: 9.162

3.  Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis.

Authors:  Guosong Jiang; Amy D Wu; Chao Huang; Jiayan Gu; Liping Zhang; Haishan Huang; Xin Liao; Jingxia Li; Dongyun Zhang; Xingruo Zeng; Honglei Jin; Haojie Huang; Chuanshu Huang
Journal:  Cancer Prev Res (Phila)       Date:  2016-04-14

4.  JAK-mediated autophagy regulates stemness and cell survival in cisplatin resistant bladder cancer cells.

Authors:  R Ojha; S K Singh; S Bhattacharyya
Journal:  Biochim Biophys Acta       Date:  2016-07-27

5.  Inhibition of STAT signalling in bladder cancer by diindolylmethane: relevance to cell adhesion, migration and proliferation.

Authors:  Yiyang Sun; Mai-Kim Cheng; Thomas R L Griffiths; J Kilian Mellon; Bao Kai; Marina Kriajevska; Margaret M Manson
Journal:  Curr Cancer Drug Targets       Date:  2013-01       Impact factor: 3.428

6.  Bladder cancers arise from distinct urothelial sub-populations.

Authors:  Jason Van Batavia; Tammer Yamany; Andrei Molotkov; Hanbin Dan; Mahesh Mansukhani; Ekaterina Batourina; Kerry Schneider; Daniel Oyon; Mark Dunlop; Xue-Ru Wu; Carlos Cordon-Cardo; Cathy Mendelsohn
Journal:  Nat Cell Biol       Date:  2014-09-14       Impact factor: 28.824

7.  Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro.

Authors:  Lars Dyrskjøt; Marie S Ostenfeld; Jesper B Bramsen; Asli N Silahtaroglu; Philippe Lamy; Ramshanker Ramanathan; Niels Fristrup; Jens L Jensen; Claus L Andersen; Karsten Zieger; Sakari Kauppinen; Benedicte P Ulhøi; Jørgen Kjems; Michael Borre; Torben F Orntoft
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

8.  Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells.

Authors:  Yong Fang; Zipeng Cao; Qi Hou; Chen Ma; Chunsuo Yao; Jingxia Li; Xue-Ru Wu; Chuanshu Huang
Journal:  Mol Cancer Ther       Date:  2013-05-30       Impact factor: 6.261

9.  Insights into the miRNA regulations in human disease genes.

Authors:  Jyotirmoy Das; Soumita Podder; Tapash Chandra Ghosh
Journal:  BMC Genomics       Date:  2014-11-21       Impact factor: 3.969

10.  Up-regulation of microRNA-145 associates with lymph node metastasis in colorectal cancer.

Authors:  Wei Yuan; Chenguang Sui; Qian Liu; Wanyan Tang; Huaying An; Jie Ma
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

View more
  13 in total

1.  miR-3687 Overexpression Promotes Bladder Cancer Cell Growth by Inhibiting the Negative Effect of FOXP1 on Cyclin E2 Transcription.

Authors:  Qipeng Xie; Caiyi Chen; Haiying Li; Jiheng Xu; Lei Wu; Yuan Yu; Shuwei Ren; Hongyan Li; Xiaohui Hua; Huiying Yan; Dapang Rao; Huxiang Zhang; Honglei Jin; Haishan Huang; Chuanshu Huang
Journal:  Mol Ther       Date:  2019-03-15       Impact factor: 11.454

Review 2.  MicroRNAs: Key Players in Bladder Cancer.

Authors:  Qi Li; Helei Wang; Hourong Peng; Qiuping Huang; Ting Huyan; Qingsheng Huang; Hui Yang; Junling Shi
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

Review 3.  Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.

Authors:  Ulrich H Weidle; Fabian Birzele
Journal:  Cancer Diagn Progn       Date:  2021-07-03

4.  MiR-145 regulates osteogenic differentiation of human adipose-derived mesenchymal stem cells through targeting FoxO1.

Authors:  Wei Hao; Hongzhi Liu; Lugang Zhou; Yujie Sun; Hao Su; Jianqiang Ni; Tian He; Peng Shi; Xin Wang
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-17

5.  EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells.

Authors:  Min Zheng; Ming-Xin Cao; Xiao-Jie Luo; Li Li; Ke Wang; Sha-Sha Wang; Hao-Fan Wang; Ya-Jie Tang; Ya-Ling Tang; Xin-Hua Liang
Journal:  J Cell Mol Med       Date:  2019-07-31       Impact factor: 5.310

6.  LncRNA MBNL1-AS1 represses cell proliferation and enhances cell apoptosis via targeting miR-135a-5p/PHLPP2/FOXO1 axis in bladder cancer.

Authors:  Xiaosong Wei; Xiaoming Yang; Beibei Wang; Yang Yang; Zhiwei Fang; Chengzhi Yi; Lei Shi; Dongkui Song
Journal:  Cancer Med       Date:  2019-11-25       Impact factor: 4.452

7.  Nuclear division cycle 80 promotes malignant progression and predicts clinical outcome in colorectal cancer.

Authors:  Xuebing Yan; Linsheng Huang; Liguo Liu; Huanlong Qin; Zhenshun Song
Journal:  Cancer Med       Date:  2018-01-17       Impact factor: 4.452

8.  MicroRNA-149* suppresses hepatic inflammatory response through antagonizing STAT3 signaling pathway.

Authors:  Qiqi Zhang; Jia Su; Ziwei Wang; Hui Qi; Zeyong Ge; Zhijun Li; Wei-Dong Chen; Yan-Dong Wang
Journal:  Oncotarget       Date:  2017-06-16

9.  STAT3 Promotes Invasion and Aerobic Glycolysis of Human Oral Squamous Cell Carcinoma via Inhibiting FoxO1.

Authors:  Min Zheng; Ming-Xin Cao; Xiang-Hua Yu; Li Li; Ke Wang; Sha-Sha Wang; Hao-Fan Wang; Ya-Jie Tang; Ya-Ling Tang; Xin-Hua Liang
Journal:  Front Oncol       Date:  2019-11-05       Impact factor: 6.244

10.  Role of microRNA in muscle regeneration and diseases related to muscle dysfunction in atrophy, cachexia, osteoporosis, and osteoarthritis.

Authors:  Joanna Brzeszczyńska; Filip Brzeszczyński; David F Hamilton; Robin McGregor; A Hamish R W Simpson
Journal:  Bone Joint Res       Date:  2020-11       Impact factor: 5.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.